• 股價
  • 漲跌
  • 漲幅
  • 成交量
Quarterly Revenue: Q4 2023 revenue increased by 4% year-over-year to $1.12 billion.
Annual Revenue: Fiscal year 2023 revenue decreased by 2% to $4.50 billion.
GAAP Diluted EPS: Q4 2023 GAAP diluted loss per share of $(1.11), fiscal year loss per share of $(7.34).
Non-GAAP Diluted EPS: Remained s
    The European Union is making life a lot more challenging for businesses across the globe.
    The 27-nation bloc has aggressively adopted new laws meant to police personal data, social media content, and the dominance of Big Tech. It has sued to block mergers. And it has readied the world’s first comp
      Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. During the quarter the strategy returned 17.6% net of fees compared to the S&P 500’s 11.7% return. The portf
        Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 14.43% (net) compared to 14.16% for the Russell 1000 Growth Index and 11.69% for the S&P 500 I
          Institutions' substantial holdings in Illumina implies that they have significant influence over the company's share price
          50% of the business is held by the top 13 shareholders
           Recent sales by insiders 
          If you want to know who really controls Illumina, Inc. (NASDAQ:ILMN), then you'll have to l
            HONG KONG (AP) — Asian shares retreated Wednesday after a lackluster session on Wall Street, though Tokyo broke ranks, gaining more than 2% as a weaker yen lifted stock prices for export manufacturers.
            U.S. futures declined while oil prices gained.
            Tokyo’s Nikkei 225 is trading near a 34-year hig
              Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.
              Investors might not be quite so excited, as Illumina entered the month more than 80% below its all-time highs from 2021.
              But hopes for a bottoming and recover